Edition:
United States

GenKyoTex SA (GKTX.PA)

GKTX.PA on Paris Stock Exchange

4.63EUR
11:35am EDT
Change (% chg)

€0.13 (+2.89%)
Prev Close
€4.50
Open
€4.75
Day's High
€4.84
Day's Low
€4.50
Volume
36,473
Avg. Vol
11,828
52-wk High
€17.80
52-wk Low
€4.14

Latest Key Developments (Source: Significant Developments)

GenKyoTex Cash And Cash Equivalents Of 10.2 Million Euros As Of December 31St, 2018
Thursday, 31 Jan 2019 12:17pm EST 

Jan 31 (Reuters) - GENKYOTEX SA ::CASH AND CASH EQUIVALENTS OF € 10.2 MILLION AS OF DECEMBER 31ST, 2018.WE CAN CONFIRM THAT THE LAST PATIENT OUT IN OUR PHASE 2 CLINICAL TRIAL IN PRIMARY BILIARY CHOLANGITIS (PBC) IS EXPECTED BY MID-MARCH - CEO.GENKYOTEX EXPECTS ITS CURRENT RESOURCES TO SUPPORT EXPECTED OPERATIONS UNTIL EARLY 2020.WE EXPECT OUR CURRENT CASH POSITION TO SUPPORT OUR STRATEGIC OBJECTIVES FOR GKT831 UNTIL EARLY 2020 - CEO.EXPECTS TO SECURE NON-DILUTIVE GRANT FINANCING TO SUPPORT ITS ONGOING COLLABORATIONS WITH ACADEMIC PARTNERS.  Full Article

Genkyotex Announces Approval Of Reverse Stock Split By Its Shareholders
Friday, 25 Jan 2019 01:00am EST 

Jan 25 (Reuters) - GENKYOTEX SA ::GENKYOTEX ANNOUNCES THE APPROVAL OF REVERSE STOCK SPLIT BY ITS SHAREHOLDERS AND PROVIDES BUSINESS UPDATE.ALL PATIENTS IN PHASE 2 TRIAL WITH GKT831 IN PBC HAVE COMPLETED A 12-WEEK TREATMENT AND APPROXIMATELY 75% HAVE COMPLETED FULL 24-WEEK TREATMENT PERIOD.NO DROPOUTS OR TREATMENT INTERRUPTIONS DUE TO PRURITUS HAVE BEEN REPORTED TO DATE.CONFIRMS THAT FINAL RESULTS OF ONGOING PHASE II TRIAL WITH GKT831 IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) WILL BE PUBLISHED IN SPRING OF 2019.THE REVERSE STOCK SPLIT OPERATIONS WILL BEGIN AS FROM FEBRUARY 27, 2019.IT IS ANTICIPATED THAT LAST PATIENTS WILL COMPLETE 24-WEEK TREATMENT PERIOD BY MID-MARCH.  Full Article

French group Genkyotex announces positive regulatory feedback for GKT831
Monday, 29 Oct 2018 02:00am EDT 

Oct 29 (Reuters) - GenKyoTex SA ::* Positive outcome from the Independent SMB’s Third Pre-Planned Review of the Phase 2 Trial of GKT831 in Primary Biliary Cholangitis.* Positive safety profile of GKT831 further supported with 87 patients at week 6 and 41 patients now having completed the full 24-week treatment period.* Interim efficacy results in early November 2018 and final results in spring 2019.  Full Article

Genkyotex Cash And Cash Equivalents At September 30 Of 12.8 Million Euros
Wednesday, 24 Oct 2018 12:03pm EDT 

Oct 24 (Reuters) - GENKYOTEX SA ::INTERIM EFFICACY RESULTS OF PHASE 2 PBC STUDY EXPECTED EARLY NOVEMBER 2018 AND FINAL RESULTS SPRING 2019.GENKYOTEX PROVIDES CORPORATE UPDATE AND REPORTS CASH POSITION AT SEPTEMBER 30, 2018.CASH AND CASH EQUIVALENTS OF EUR 12.8 MILLION AS OF SEPTEMBER 30, 2018 PROVIDING CASH RUNWAY TO END Q3 2019.  Full Article

Genkyotex reports Preclinical Efficacy Of GKT831 In Prostate Cancer
Monday, 8 Oct 2018 01:00am EDT 

Oct 8 (Reuters) - GENKYOTEX SA ::PRECLINICAL EFFICACY OF GENKYOTEX’S GKT831 IN PROSTATE CANCER PRESENTED AT ESUR18 MEETING.DATA DEMONSTRATE POTENTIAL OF GKT831 TO EFFICIENTLY TARGET CANCER ASSOCIATED FIBROBLASTS.INTERIM RESULTS OF PHASE 2 TRIAL WITH GKT831 IN PRIMARY BILIARY CHOLANGITIS EXPECTED IN EARLY NOVEMBER 2018.SAFETY AND EFFICACY OF GKT831 IS CURRENTLY BEING ASSESSED IN TWO SEPARATE PHASE 2 TRIALS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AND DIABETIC KIDNEY DISEASE, TWO PROGRESSIVE FIBROTIC DISORDERS.  Full Article

Genkyotex Net Loss Narrows To 4.8 Million Euros
Wednesday, 26 Sep 2018 11:45am EDT 

Sept 27 (Reuters) - GENKYOTEX SA ::GENKYOTEX ANNOUNCED ON WEDNESDAY FIRST-HALF 2018 FINANCIAL RESULTS.CASH AND CASH EQUIVALENTS OF EUR 9.3 MILLION AT JUNE 30, 2018.H1 NET LOSS EUR 4.8 MILLION VERSUS LOSS EUR 20.4 MILLION YEAR AGO.H1 OPERATING LOSS EUR 4.8 MILLION VERSUS LOSS OF EUR 20.3 MILLION YEAR AGO.INTERIM RESULTS OF PHASE 2 TRIAL OF GKT831 IN PATIENTS WITH PBC EXPECTED IN EARLY NOVEMBER 2018.  Full Article

Genkyotex Announces Positive Outcome From The Second Smb Review Of The Phase 2 Trial Of Gkt831
Monday, 3 Sep 2018 11:45am EDT 

Sept 3 (Reuters) - GenKyoTex SA ::GENKYOTEX ANNOUNCES POSITIVE OUTCOME FROM THE SECOND INDEPENDENT SMB REVIEW OF THE PHASE 2 TRIAL OF GKT831 IN PRIMARY BILIARY CHOLANGITIS.SMB REVIEWED 77 PATIENTS INCLUDING 60 WHO HAVE REACHED 6 WEEKS OF TREATMENT.ENROLLMENT IN INTERIM ANALYSIS COHORT OF 90 PATIENTS HAS BEEN COMPLETED.SAYS POSITIVE OUTCOME OF THIS SECOND INDEPENDENT SMB MEETING FURTHER SUPPORTS POSITIVE CLINICAL SAFETY PROFILE OF GKT831.EXPECTS INTERIM EFFICACY RESULTS IN FALL 2018 AND FINAL RESULTS IN FIRST HALF OF 2019.SMB RECOMMENDED CONTINUATION OF STUDY AS PER PROTOCOL, WITH NO CHANGES OR ADDITIONAL DATA COLLECTION REQUIRED.ALSO INTENDS TO INITIATE AN OPEN-LABEL EXTENSION STUDY FOR PATIENTS COMPLETING ONGOING PHASE 2 TRIAL.SAYS INTENDS TO INITIATE AN OPEN-LABEL EXTENSION STUDY FOR PATIENTS COMPLETING ONGOING PHASE 2 TRIAL.  Full Article

GenKyoTex Announces Phase 2 Clinical Trial Of GKT831 In Idiopathic Pulmonary Fibrosis Patients
Tuesday, 31 Jul 2018 12:00pm EDT 

July 31 (Reuters) - GENKYOTEX SA ::GENKYOTEX ANNOUNCES INVESTIGATOR-INITIATED PHASE 2 CLINICAL TRIAL TO BE CONDUCTED WITH GKT831 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS.TRIAL TO BE FULLY FUNDED VIA A GRANT FROM UNITED STATES NATIONAL INSTITUTES OF HEALTH TO A CONSORTIUM OF LEADING ACADEMIC INSTITUTIONS.PATIENT ENROLLMENT IS EXPECTED TO BEGIN DURING FIRST HALF OF 2019.KEY SECONDARY ENDPOINTS INCLUDE CHANGES IN 6-MINUTE WALK DISTANCE, FORCED VITAL CAPACITY AND HIGH-RESOLUTION CT.PRIMARY ENDPOINT OF STUDY WILL BE CHANGE IN PLASMA LEVELS, AT END OF 24-WEEK TREATMENT PERIOD, OF O,O'-DITYROSINE.  Full Article

Genkyotex Expands License Agreement For Vaxiclase Platform With Serum Institute Of India
Monday, 25 Jun 2018 01:00am EDT 

June 25 (Reuters) - GENKYOTEX SA ::GENKYOTEX EXPANDS LICENSE AGREEMENT FOR VAXICLASE PLATFORM WITH SERUM INSTITUTE OF INDIA.FOR NEW TERRITORIES GENKYOTEX IS ELIGIBLE TO RECEIVE UP TO EUR 100 MILLION INCLUDING AN UPFRONT PAYMENT, DEVELOPMENT AND COMMERCIAL MILESTONES.THIS BRINGS OVERALL AGREEMENT TO APPROXIMATELY EUR 150 MILLION*.LICENSED TERRITORIES ARE EXTENDED TO DEVELOPED WORLD MAJOR PHARMACEUTICAL MARKETS.SERUM INSTITUTE OF INDIA TO DEVELOP PERTUSSIS VACCINE USING THE VAXICLASE PLATFORM.  Full Article

GenKyoTex cash & cash equivalents and liquid investments at 15.3 million euros as of Sept 30​
Thursday, 26 Oct 2017 12:01pm EDT 

Oct 26 (Reuters) - Genkyotex Sa ::‍TWO PHASE 2 CLINICAL TRIALS IN FIBROTIC INDICATIONS PROGRESSING ON TRACK IN Q3​.‍FIRST PUBLICATION HIGHLIGHTING GKT831 IN ONCOLOGY MODELS IN Q3​.‍CASH & CASH EQUIVALENTS AND LIQUID INVESTMENTS OF EUR 15.3 MILLION AS OF SEPT 30​.‍PHASE 2 CLINICAL TRIAL OF GKT831 ON TRACK TO DELIVER INTERIM RESULTS IN H1 2018​.‍P PHASE 2 CLINICAL TRIAL OF GKT831 TO DELIVER FULL RESULTS IN H2 2018​.‍ SECOND PHASE 2 TRIAL WITH GKT831 ON TRACK TO ENROLL FIRST PATIENT BY END OF 2017​.‍ GKT831 TRIAL WILL INCLUDE 142 PATIENTS​.‍CO EXPECTS TO RECEIVE A RESEARCH TAX CREDIT (CRÉDIT IMPÔT RECHERCHE) FOR YEAR 2016 FILED BY GENTICEL OF EUR 2.4 MILLION​.  Full Article